argenx NV ADR
$ 834.55
0.17%
11 Feb - close price
- Market Cap 51,558,777,000 USD
- Current Price $ 834.55
- High / Low $ 837.54 / 822.60
- Stock P/E 35.59
- Book Value 99.66
- EPS 23.41
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.25 %
- 52 Week High 934.62
- 52 Week Low 510.06
About
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Analyst Target Price
$1040.85
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-15 | 2025-05-07 | 2025-02-27 | 2024-10-31 | 2024-07-25 | 2024-05-09 | 2024-02-29 | 2023-10-31 | 2023-07-27 | 2023-05-07 | 2023-03-02 |
| Reported EPS | 5.18 | 3.2572 | 2.2732 | 0.7125 | 1.39 | 0.45 | -1.04 | -1.68 | -1.25 | -1.69 | -0.71 | -0.7 |
| Estimated EPS | 4.44 | -0.99 | 2.0546 | 1.6979 | 0.03 | -0.98 | -0.86 | -1.7 | -1.54 | -1.73 | -2.26 | -0.7 |
| Surprise | 0.74 | 4.2472 | 0.2186 | -0.9854 | 1.36 | 1.43 | -0.18 | 0.02 | 0.29 | 0.04 | 1.55 | 0 |
| Surprise Percentage | 16.6667% | 429.0101% | 10.6395% | -58.0364% | 4533.3333% | 145.9184% | -20.9302% | 1.1765% | 18.8312% | 2.3121% | 68.5841% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 6.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARGX
2026-02-06 08:33:00
Baron Health Care Fund's Q4 2025 investor letter highlighted Argenx SE (NASDAQ:ARGX) as a key contributor to its performance, largely due to stronger-than-expected sales of its drug Vyvgart. The biopharma company's shares gained 26.86% over the last 52 weeks, driven by successful launches in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with anticipated efficacy in more autoimmune conditions. The fund remains optimistic about Vyvgart's long-term growth potential and Argenx's pipeline.
2026-01-30 08:00:30
Argenx's Vyvgart sales are exceeding expectations for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) treatments, with strong momentum projected through 2026. William Blair maintained an Outperform rating on Argenx SE (ARGX), highlighting Vyvgart's performance and the potential of other clinical products like empasiprubart. The FDA has also granted priority review for a supplemental biologics licensing application to expand Vyvgart's use in generalized myasthenia gravis.
2026-01-29 15:03:00
Wells Fargo has increased its price target for Argenx SE (NASDAQ: ARGX) to $1,317, maintaining an Overweight rating due to the strong outlook for its drug Vyvgart. Analyst Derek Archila raised the 2026-2030 Vyvgart outlook by 5-15%, believing the company's FY2026 consensus estimate of $5.6 billion is too low and projecting $6.5 billion. The stock has seen a significant surge of over 45% in the past six months, with 86% of analysts rating it a "Buy."
2026-01-29 09:59:18
Wells Fargo has increased its price target for Argenx SE (ARGX) to $1,317, maintaining an Overweight rating, citing strong potential for its autoimmune disease drug, Vyvgart. Analyst Derek Archila anticipates Argenx to exceed its FY2026 consensus estimate, projecting $6.5 billion in revenue. This optimistic outlook follows a significant rise in Argenx shares and a high "Buy" rating from analysts.
2026-01-28 14:59:53
This article summarizes a bullish thesis on argenx SE (ARGX) by Lux Opes Research, highlighting the strong performance of its drug VYVGART, which generated over $4.1 billion in 2025. The company is expanding VYVGART's indications and global footprint while also building a robust pipeline of next-generation molecules. Argenx is transitioning into a platform-driven commercial organization with multiple opportunities for sustained value creation.
2026-01-28 07:59:18
Argenx SE (NASDAQ: ARGX) stock advanced due to continued commercial execution and pipeline progress, according to ClearBridge Investments' Q4 2025 investor letter. The immunology-focused biotechnology company closed at $864.42 per share on January 27, 2026, with a market capitalization of $53.493 billion. While hedge fund holdings decreased slightly, ClearBridge noted positive performance despite overall challenges in the healthcare sector for their strategy.
